Worried that you are at risk for developing Alzheimer’s Disease? Join the A4 Prevention Study Today!
Latest statistics show that there are more than 700,00 people in Canada living with Alzheimer’s Disease or other dementias and as baby boomers age that number is expected to double by 2031.
The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Study) is at the forefront of research and aims to determine whether an anti-amyloid antibody, Solanezumab can slow down the progression of Alzheimer’s Disease. This study is eligible to individuals between 65 and 85 years of age who are at risk of developing the disease and are looking for potential prevention treatments even before they start noticing symptoms. Screening for participation includes a brain PET scan which assesses for the presence of amyloid protein plaques, which are the hallmark finding in Alzheimer’s Disease.
To learn more about this trial, please speak with one of our research staff at 416-386-9606 or visit our Research Program Page.